Small compound 6-O-angeloylplenolin induces caspase-dependent apoptosis in human multiple myeloma cells

YING LIU1*, YING DONG2*, BO ZHANG3 and YONG-XIAN CHENG4

1The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech and BioMedicine and Division of Life Sciences, Shenzhen Graduate School, Tsinghua University, Shenzhen, Guangdong 518055; 2Department of Oncology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009; 3National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101; 4State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650204, P.R. China

Received January 3, 2013; Accepted May 17, 2013

DOI: 10.3892/ol.2013.1370

Correspondence to: Dr Ying Liu, The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech and BioMedicine and Division of Life Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen, Guangdong 518055, P.R. China
E-mail: liu.ying2012@sz.tsinghua.edu.cn

Dr Yong-Xian Cheng, State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, 132 Lanhei Road, Kunming, Yunnan 650204, P.R. China
Email: yxcheng@mail.kib.ac.cn

*Contributed equally

Key words: 6-O-angeloylplenolin, multiple myeloma, apoptosis, caspase

Abstract. 6-O-angeloylplenolin (6-OAP) is a sesquiterpene lactone agent that has been previously demonstrated to inhibit the growth of multiple myeloma (MM) cells through mitotic arrest with accumulated cyclin B1. In the present study, the levels of apoptosis were analyzed in dexamethasone-sensitive (MM.1S), dexamethasone-resistant (U266) and chemotherapy-sensitive (RPMI 8226) myeloma cell lines. Enhanced apoptosis was identified following a 48-h incubation with 6-OAP (0-10 µM) that induced a dose-dependent decrease in pro-casp-3 and the cleavage of its substrate, anti-poly(ADP-ribose) polymerase (PARP). In addition, time-dependent cleavage of PARP was also detected in U266 and MM.1S cells. The mechanism of 6-OAP cytotoxicity in all cell lines was associated with the induction of apoptosis with the presence of cleaved caspase-3 and PARP. In conclusion, 6-OAP-induced apoptosis is caspase-dependent. These observations are likely to provide a framework for future studies of 6-OAP therapy in MM.

Introduction

Multiple myeloma (MM) or plasma cell myeloma is a malignant disorder characterized by the accumulation of differentiated B cells (plasma cells). The incompletely differentiated plasma cells are characterized by deregulated apoptosis (1). The treatment of MM remains unsatisfactory and new agents that specifically target key signaling pathways required for myeloma growth or survival are urgently required.

6-O-angeloylplenolin (6-OAP; Fig 1A) is a sesquiterpene lactone isolated from Centipeda minima that has been studied in hematological and solid forms of cancer and has been revealed to exhibit activity without significant toxicity (2-4). The results of our preliminary study demonstrated that 6-OAP inhibits the proliferation of human MM cells by inducing the arrest of mitosis and inhibiting specific key pathways (5). However, whether 6-OAP-induced mitosis arrest and pathway inhibition are followed by apoptosis requires further study. Therefore, the aim of the present study was to investigate the apoptotic effect of 6-OAP against human myeloma cells.

Materials and methods

Reagents. 6-OAP with a purity ≥99.5% was extracted from Centipeda minima (L.) as described previously (4). The 6-OAP was then dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, USA) to produce a stock solution of 10⁻² M, which was stored at -20°C.

Cell culture. MM.1S, U266 and RPMI 8226 human MM cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in RPMI-1640 medium supplemented with 10% (for U266) or 15% (for RPMI 8226 and MM.1S) fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT, USA) and incubated in a humidified atmosphere with 5% CO₂ at 37°C.

Patient samples. CD138+ cells from a single patient with MM were isolated with informed consent from bone marrow (BM) mononuclear cells using positive immunomagnetic column
LIU et al.: EFFECTS OF 6-O-ANGELOYLPLENOLIN ON HUMAN MULTIPLE MYELOMA CELLS

The purity of the CD138⁺ cells was >97% as determined by flow cytometry. This study was approved by the ethics committee of Shenzhen Graduate School, Tsinghua University, Shenzhen, China.

DNA fragmentation. The MM cells were collected and lysed in 0.5 ml lysis buffer containing 10 mM Tris (pH 8.0), 10 mM EDTA and 0.05% Triton X-100. The lysate was centrifuged, RNase (0.2 mg/ml) was added and the lysate was incubated for 30 min at 37°C. Proteinase K (0.1 ng/ml) and sodium dodecyl sulfate (SDS; final concentration 1%) were added, followed by incubation at 50°C for 16 h. DNA was extracted with phenol/chloroform and then chloroform, prior to being precipitated with ethanol and sodium acetate and electrophoresed on 1.5% agarose gels, and then visualized with ethidium bromide (EB) staining.

Flow cytometric assays for Annexin-V (AV). Cell apoptosis was evaluated by AV detection using an AV-FITC kit (BD Biosciences, Franklin Lakes, NJ, USA), according to the manufacturer's instructions.

Western blot. Cell pellets were lysed in RIPA buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP-40, 1 mM DTT, 1 mM NaF, 1 mM sodium vanadate and a protease inhibitor cocktail (Sigma-Aldrich). Protein extracts were quantitated, loaded on 8-12% SDS-polyacrylamide gels, electrophoresed and then transferred to a nitrocellulose membrane (Whatman plc, Maidstone, Kent). The membrane was incubated with primary antibody, washed and incubated with horseradish peroxidase-conjugated secondary antibody. Detection was performed using a chemiluminescent western detection kit (Cell Signaling Technology, Inc., Danvers, MA, USA). The antibodies used were anti-caspase-3, anti-poly (ADP-ribose) polymerase (PARP; Cell Signaling Technology, Inc.) and anti-β-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).

Statistical analysis. All experiments were repeated at least three times and the data are presented as the mean ± SD unless noted otherwise. P<0.05 was considered to indicate a statistically significant difference.

Results

6-OAP induces apoptosis in MM cells. The levels of apoptosis were analyzed using the DNA fragmentation assay in dexa-
methasone-sensitive (MM.1S) and dexamethasone-resistant (U266) myeloma cell lines treated with 6-OAP. As demonstrated in Fig. 1B, marked DNA ladders were observed in MM.1S and U266 cells treated with 6-OAP, indicative of apoptosis detection.

In addition, AV staining was conducted to assess apoptosis in U266 and chemotheraphy-sensitive RPMI 8226 cell lines treated with 6-OAP. Using flow cytometry, 7.5 μM 6-OAP was identified to induce apoptosis at a ratio of 28 and 46% in U266 and RPMI 8226 cells, respectively (Fig. 2). These results indicate that 6-OAP induces apoptosis in MM cells.

6-OAP-induced apoptosis in MM cells is caspase-dependent. The apoptotic pathways that ultimately lead to the activation of effector caspases (casp-3, -2 and -7) and the cleavage of PARP have been characterized in MM (6). Therefore, a western blot analysis was used to detect the activation of the casp-3 effector caspase and its substrate, PARP, in the MM cells. 6-OAP was demonstrated to induce a significant dose-dependent decrease in pro-casp-3 and the cleavage of its substrate, PARP, in the three cell lines, indicating the activation of casp-3 (Fig. 3A). 6-OAP also markedly induced the cleavage of PARP in a time-dependent manner in the U266 and MM.1S cells (Fig. 3B). In addition, the expression of pro-casp-3 and the cleavage of PARP was investigated in CD138+ primary cells isolated from a single MM patient (Fig. 3C). The results of the western blot analysis demonstrated that 6-OAP significantly induces the activation of casp-3. These observations indicate that 6-OAP induces caspase-dependent apoptosis in MM cells.

Discussion

The natural agent, 6-OAP, was initially demonstrated to exhibit anti-bacterial and anti-protozoal activities (7-9). However, more recently, studies have demonstrated an anti-tumor activity for 6-OAP in solid tumors and hematological malignancies (2-4). Our previous observations found that 6-OAP induces the arrest of mitosis in MM cells by the activation of the spindle assembly checkpoint and the accumulation of cyclin B1. In addition, 6-OAP was identified to inhibit the Jak2/Stat3 and Akt signaling pathways, thereby blocking the facilitation of the BM microenvironment on the MM cells. 6-OAP has also been found to induce marked inhibition of NF-κB in MM cells (5). However, to date, no studies have determined whether the inhibitory effects of 6-OAP on the cell cycle and certain signal pathways ultimately result in apoptosis. Therefore, in the present study, the effect of 6-OAP on apoptosis in MM cells was analyzed.

Apoptosis is an active process that ultimately leads to the activation of endonucleases and the cleavage of DNA into fragments of 180-200 bp. The extrinsic and intrinsic apoptotic pathways that ultimately lead to activation of effector caspases (casp-3, -2 and -7) have also been characterized (10,11). The present study demonstrated that 6-OAP-treated MM cells exhibited evident DNA fragments of 180-200 bp (Fig. 1B), indicating that 6-OAP induces apoptosis in MM cells. The activation of the effector caspases was also analyzed and 6-OAP was found to induce casp-3 activation, followed by PARP cleavage in various MM cell lines (Fig. 3), indicating that 6-OAP induces caspase-dependent apoptosis in MM cells. In conclusion, 6-OAP induces growth inhibition in human MM cells using a number of different mechanisms, including the arrest of mitosis and the inhibition of certain signaling pathways. These different mechanisms ultimately lead to caspase-dependent apoptotic cell death.

Acknowledgements

This study was supported, in part, by the National Natural Science Foundation of China (No. 81101835) and the Foundation of Zhejiang Provincial Education Department (No. Y200804683).

References

1. Chauhan D and Anderson KC: Apoptosis in multiple myeloma: therapeutic implications. Apoptosis 6: 47-55, 2001.
2. Changlong L, Hezhen W, Yongping H, Yanfang Y, Yanwen L and Jianwen L: 6-O-Angeloylenolind induces apoptosis through a mitochondrial/caspase and NF-kappaB pathway in human leukemia HL60 cells. Biomed Pharmacother: 62: 401-409, 2008.
3. Su M, Chung HY and Li Y: 6-O-Angeloylenolinduced cell-cycle arrest and apoptosis in human nasopharyngeal cancer cells. Chem Biol Interact 189: 167-176, 2011.
4. Ding LF, Liu Y, Liang HX, Liu DP, Zhou GB and Cheng YX: Two new terpene glucosides and antitumor agents from Centipeda minima. J Asian Nat Prod Res 11: 732-736, 2009.
5. Liu Y, Chen XQ, Liang HX, Zhang FX, Zhang B, Jin J, Chen YL, Cheng YX and Zhou GB: Small compound 6-o-angeloylenolind induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. PLoS One 6: e21930, 2011.
6. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001.
7. Taylor RS and Towers GH: Antibacterial constituents of the Nepalese medicinal herb, Centipeda minima. Phytochemistry 47: 631-634, 1998.
8. Francois G, Passreiter CM, Woerdnbag HJ and Van LM: Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from Neurulaena lobata. Planta Med 62: 126-129, 1996.
9. Schwikard S and van Heerden FR: Antimalarial activity of plant metabolites. Nat Prod Rep 19: 675-692, 2002.
10. Nicholson DW: Caspase structure, proteolytic substrates and function during apoptotic cell death. Cell Death Differ 6: 1028-1042, 1999.
11. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.